2025-05-29-Jefferies-阿尔肯实验室（ALKEM）_阿尔肯实验室第四季度业绩未达预期_转向加速增长_有待执行_表现不佳评级_13页_686kb

Alkem Laboratories Summary

Core Content

Alkem Laboratories, a leading Indian pharmaceutical company, reported its fourth-quarter results, which fell short of estimates. The company has shifted its focus from margin improvement to accelerating revenue growth, a strategic pivot that comes with increased R&D and operational costs.

Main Points

• 4Q Performance:

  • Revenue: INR31.4bn (+7% YoY/-7% QoQ), 2% below estimates.
  • EBITDA: INR3.9bn (-3% YoY/-48% QoQ), 8% below estimates.
  • PAT: INR3bn (+4% YoY/-51% QoQ), 9% below estimates.
  • EBITDA margins: 12.4%, down 125bps YoY due to weak gross margins.

• Growth Strategy:

  • Alkem has pivoted to accelerate revenue growth after 18 months of margin improvement.
  • For FY26, it expects high single-digit revenue growth, with India outperforming the industry by 1ppt.
  • For FY27, double-digit revenue growth is anticipated.

• Margin Impact:

  • EBITDA margins are expected to remain flat at ~19.5% in FY26 due to increased R&D spend and other costs.
  • The company aims to file 8-9 ANDAs in FY26 for US and RoW markets, which will require higher upfront costs.

• Financial Guidance:

  • R&D spend is expected to increase to 5% of sales in FY26 from 4.4% in FY25.
  • SG&A spend to sales is expected to remain stable.
  • Tax rate for FY26 is guided at 13-15%, increasing to 35-37% in FY27 due to loss of tax benefits.

• Capital Expenditure:

  • Capex for FY25 was INR7bn, with a similar amount expected for FY26.
  • INR2bn will be allocated to Enzene, its biotech subsidiary.

• Valuation and Target:

  • Price target reduced to INR4,460 from INR4,580, reflecting a 15% drop.
  • Valuation is based on 22x Mar-27 EPS.
  • The company's valuation multiples are projected to decline over the forecast period.

• Market Segments:

  • India: Revenue grew 8% YoY, despite softer growth in trade generics.
  • US: Sales declined 5% QoQ, with growth expected to be challenging due to price erosion.
  • RoW: Sales grew 28% YoY, outperforming expectations.

• EPS Projections:

  • FY26: INR195.02 (down 6% from previous estimate).
  • FY27: INR202.52 (down 3% from previous estimate).
  • FY28: INR230.69.

• Key Metrics:

  • Revenue is expected to grow at 9% CAGR from FY25 to FY27.
  • EBITDA is projected to increase from INR25,122m in FY25 to INR35,411m in FY28.
  • Net Profit is expected to rise from INR21,660m in FY25 to INR27,583m in FY28.
  • ROCE and ROE remain stable at 17% and 16% respectively for FY26-28.

• Balance Sheet:

  • Cash and equivalents are projected to increase significantly from INR17,283m in FY24 to INR75,777m in FY28.
  • Total assets are expected to grow from INR155,749m in FY24 to INR236,156m in FY28.
  • Shareholder's equity is forecasted to increase from INR107,144m in FY24 to INR183,568m in FY28.

• Investment Thesis:

  • The company's pivot to growth is seen as a positive shift, but execution remains critical.
  • The analysts have reduced their EPS estimates for FY26 and FY27 by 3-6% due to higher R&D costs.
  • The current rating is Underperform, with a price target of INR4,460.

Key Information

• Strategic Shift: Alkem has moved from margin improvement to revenue growth.
• Execution Risk: The success of the new strategy depends on effective implementation.
• R&D Investment: Increased R&D spending will impact margins but is necessary for growth.
• Market Challenges: US market conditions are expected to remain tough due to price erosion.
• Valuation Adjustments: The price target has been lowered, reflecting reduced growth and margin expectations.
• Long-Term Outlook: Revenue growth is expected to continue, with margin improvements projected gradually.

Catalysts

• Slower revenue growth.
• Tough US market conditions.
• Potential for new product launches in the US.
• Changes in tax rates and ESG-related disclosures.

ESG Considerations

• Alkem is focused on maintaining ethical sales practices.
• The company aims to increase the percentage of women in its workforce and reduce energy consumption through efficient equipment and biomass usage.
• Questions remain about future ESG-related disclosures and long-term sustainability goals.

Analysts

• Alok Dalal and Dhawal Khut are the equity analysts involved in the report.
• The report is subject to FINRA regulations, and the analysts are not registered as research analysts with FINRA.

Investment Recommendation

• The rating is Underperform, with a price target of INR4,460.
• The report emphasizes the need for strong execution to achieve the growth targets.